TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
May 25, 2023 10:00 JST
Source:
Avance Clinical
Avance Clinical Joins Global Health Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies
ADELAIDE, AUS & SAN DIEGO, May 25, 2023 - (ACN Newswire) - Avance Clinical the leading award-winning Australian and North American CRO that offers the programs ClinicReady and GlobalReady for early phase biotech companies to speed up the path to regulatory approval, has been invited to join the Global Health Summit campaign which will be featured on Reuters.
Avance Clinical CEO, Yvonne Lungershausen, Chief Scientific Officer Gabriel Kremmidiotis, and Head of Scientific and Regulatory Affairs Jorgen Mould are interviewed in a new Global Health video featured on Reuters news service about the importance of quality clinical trials as part of the drug development process.
The campaign is a collection of interviews and video documentaries, highlighting international business leaders and healthcare specialists from various industries. The series will showcase organisations spearheading specific health initiatives, developing ground-breaking medicine and complex health technologies, and taking on the challenges of both physical and mental health globally.
The Global Health program launches at the upcoming Global Health Summit on 25-27 May 2023 at the prestigious Intercontinental Hotel in Geneva, bringing together 100 leaders and executives from various sectors of the Private and Public Healthcare Industry.
The event will feature round table discussions where participants will discuss strategies, share knowledge and expertise, and identify opportunities for collaboration. This will be complemented by keynote speeches and panel discussions that will explore the latest trends and emerging issues in the healthcare industry.
Avance Clinical CEO, Yvonne Lungershausen and Executive VP North American Operations John Mann will be attending the Global Health Summit and Yvonne will be a leading panelist. Avance Clinical is at the cutting edge of clinical trial technology and has recently been ranked as the world leader in DCT technology adoption by GlobalData and Clinical Trial Arena in the CRO sector.
The report found 46% of Avance Clinical's trials incorporated some elements of DCT technologies in 2022 including telemedicine, remote monitoring, and digital data collection. The DCT report also noted that Avance Clinical's staff training in the latest technologies was a key factor in the ranking. See the full report here.
https://www.clinicaltrialsarena.com/features/year-in-review-dct-2022/
Avance Clinical's unique clinical offering GlobalReady enables biotechs that have completed early to mid-phases in Australia to rapidly and seamlessly transition to the US in preparation for FDA approvals, all with the one CRO and dedicated teams across both regions, which reduces time and cost and delivers quality data.
There are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which demonstrates Australian data acceptability with the FDA and other major regulatory authorities.
More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program.
This seamless GlobalReady journey is designed so biotechs can:
- Take advantage of the Australian early-phase clinical trial landscape (No IND and 43.5% tax rebate)
- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)
- Seamlessly operationalize global dose-escalation and dose-expansion trials across the two regions
- Harness significant speed and cost advantages
- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities
Find out more:
- Learn about the Australian Advantage here
https://www.avancecro.com/the-australian-advantage/
- Learn about the ClinicReady model here
https://www.avancecro.com/about-clinicready/
- Learn about the GlobalReady model here
https://www.avancecro.com/avance-clinical-north-america-operations/
or more information about the benefits of running your next study with Avance Clinical
contact us:
enquiries@avancecro.com
About Avance Clinical
Avance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than 24 years.
Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.
www.avancecro.com
Media Contact:
Avance Clinical
Kate Thompson
media@avancecro.com
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical
May 31 2024 16:00 JST
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
May 08 2024 09:00 JST
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
April 19 2024 16:00 JST
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
March 28 2024 14:42 JST
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
February 28 2024 08:00 JST
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
January 12 2024 16:00 JST
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023
April 18 2023 11:00 JST
Avance Clinical Celebrates GlobalReady Success as 40 Biotechs Join Program
January 11 2023 15:00 JST
More Press release >>
Latest Press Release
Mitsubishi Power to Supply Technology to Support Brazil's Largest Reliability Project
May 31, 2024 17:09 JST
Team HRC Participation in the Suzuka 8 Hours Endurance Road Race 45th Tournament
May 31, 2024 14:59 JST
DOCOMO Launches Japan's First Demonstration Experiment of Self-powered Hydropower Base Station
May 30, 2024 14:30 JST
Fujitsu leverages data and AI to enable Panasonic EW's resilient supply chain management
May 29, 2024 15:27 JST
Hydrogen Engine Generator Set Ready for In-house Evaluation
May 29, 2024 13:53 JST
Hitachi and Google Cloud Announce Strategic Partnership to Accelerate Innovation and Productivity with Generative AI
May 29, 2024 12:38 JST
Japanese Consortium Achieves World's First Demonstration of 5G Communication from Altitude of 4km Using 38GHz Band
May 29, 2024 11:44 JST
Hitachi High-Tech Launches the SU3900SE and SU3800SE Series High-Resolution Schottky Field Emission Scanning Electron Microscopes Allowing Observation of Large and Heavy Samples at the Nano Level
May 29, 2024 11:30 JST
Celonis and NEC begin Proof of Concept Integrating Generative AI and Process Intelligence
May 28, 2024 20:20 JST
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
May 28, 2024 15:19 JST
Roche and Hitachi High-Tech extend their long-standing partnership
May 28, 2024 12:53 JST
Subaru, Toyota, and Mazda Commit to New Engine Development for the Electrification Era, Toward Carbon Neutrality
May 28, 2024 12:45 JST
Fujitsu unveils 1FINITY T250, an optical transmission solution that enables new connectivity services to achieve IOWN initiative
May 28, 2024 10:45 JST
Idemitsu Kosan, ENEOS, Toyota, and MHI Commence Study toward Introduction and Spread of Carbon-Neutral Fuels for Automobiles
May 27, 2024 13:35 JST
Toyota: Evolved Liquid Hydrogen-Powered GR Corolla to Participate in Super Taikyu Fuji 24 Hours Race
May 24, 2024 16:19 JST
Hitachi Energy's HVDC technology to power Marinus Link, a key step toward Australia's Net Zero ambitions
May 24, 2024 14:39 JST
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
May 23, 2024 18:07 JST
MHI Thermal Systems Receives JSRAE Technology Award for "e-3D Scroll" Compressor
May 23, 2024 16:01 JST
NEC X Invests in Agtech Startup Verdi, Integrates AI-Powered Platform with NEC's Cropscope Smart Farming Initiative
May 23, 2024 11:20 JST
'Fujitsu Technology and Service Vision 2024': Leveraging AI and leading-edge technologies to deliver greater value to the environment, economies and people's well-being
May 23, 2024 10:18 JST
More Latest Release >>